The company continues to strengthen its market share in the Consumer Healthcare segment.
The result is due to the sustained efforts of the company to maintain investments at a competitive level throughout 2020, but also to constantly improve, in terms of image and effective communication, the brands portfolio.
Also, Biofarm's market share has grown steadily in 10 of 12 months of 2020. No less than 7 brands in the digestive & metabolism, cold & flu and food supplements categories have maintained their position as market leaders, in terms of consumption, and 5 of them ensured the consolidation of leadership and value in the CHC segment.
Thus, at the end of the year, Biofarm gained a position in the top companies for local pharmaceutical industry, regarding Consumer Healthcare (CHC) category, compared to the purchase price of pharmacies, and ended the year in 4th place.
"After a difficult year, with many challenges, we managed to reach our goals set for 2020 and consolidate our market share. All these results represent the work of a visionary strategy and of our teams, which with dedication and a deep understanding of the context have made every effort so that even in the midst of a pandemic we can come to the aid of our customers and respond to their needs. We have been on the Romanian market for 100 years and we keep our motivation to increase the quality of people's lives, always being oriented towards innovation and facilitating access to modern treatment solutions.", Cătălin Vicol, General Manager Biofarm.
The company understands its role as a major player in the Romanian pharmaceutical market and its responsibility to its customers so Biofarm joined the Covid-19 fight last year. The manufacturer donated 1.5 million lei for the purchase of protective equipment for medical staff and special equipment.
In the context of the health crisis generated by the Covid-19 pandemic, Biofarm has taken all measures to ensure that the company's activity continues without syncope. The company has also implemented internally all health safety measures to prevent the spread of the virus, according to legal regulations. Thus, some of the company's employees continue to work from home, while the teams involved in the manufacturing process follow a program adapted to the situation, but which allows production to operate at full capacity. Moreover, preventive testing for SARS-CoV-2 of employees were made and workspaces were adapted to social distancing by limiting the number of employees present in a certain time interval in the common workspace.
For 2021, Biofarm aims to steadily increase market share, streamline operations and strengthen the competitive advantage of the product portfolio.